Safety and efficacy of apixaban and rivaroxaban in obese patients with acute venous thrombosis/embolism

Eur J Haematol. 2022 Oct;109(4):409-412. doi: 10.1111/ejh.13817. Epub 2022 Jul 13.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Oral
  • Anticoagulants / therapeutic use
  • Embolism*
  • Factor Xa Inhibitors / adverse effects
  • Humans
  • Obesity / complications
  • Obesity / drug therapy
  • Pyrazoles
  • Pyridones / adverse effects
  • Rivaroxaban / adverse effects
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / etiology
  • Venous Thrombosis* / diagnosis
  • Venous Thrombosis* / drug therapy
  • Venous Thrombosis* / etiology

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban